Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study-Reference-Cited by-同舟云学术

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

Published:2013-01-18 Issue:2 Volume:168 Page:412-421
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Papp K.A.,Langley R.G.,Sigurgeirsson B.,Abe M.,Baker D.R.,Konno P.,Haemmerle S.,Thurston H.J.,Papavassilis C.,Richards H.B.

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.12110/fullpdf

Reference16 articles.

1. Latitude and psoriasis prevalence;Jacobson;J Am Acad Dermatol,2011

2. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis;Sa;J Immunol,2007

3. Pathogenesis and therapy of psoriasis;Lowes;Nature,2007

4. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis;Chiricozzi;J Invest Dermatol,2011

5. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells;Lowes;J Invest Dermatol,2008

Cited by 325 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects;Drug Design, Development and Therapy;2024-08

3. Autoimmunity: the neoantigen hypothesis;Frontiers in Immunology;2024-06-27

4. The Intersection of the Pathogenic Processes Underlying Psoriasis and the Comorbid Condition of Obesity;Life;2024-06-07

5. “I Was Almost in Disbelief” - Qualitative Analysis of Experiences and Expectations Among Psoriasis Patients Undergoing Biologic Treatment with Secukinumab;Patient Preference and Adherence;2024-06